Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

Trial Details

NCT ID

NCT04322617

Phase

PHASE2 / PHASE3

Sponsor

Hunan Province Tumor Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Anlotinib plus the same Immune Checkpoint Inhibitors.
Anlotinib plus the new Immune Checkpoint Inhibitors.
Anlotinib

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
Age ≥ 18 years.
Histopathology or cytology confirmed lung cancer
Failed from first line Chemo-immunotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →